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Insulin resistance in uremia mediated by postbinding defects
DOUGLAS SMITH and RALPH A. DEFRONZO
The Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
Insulin resistance in uremia mediated by postbinding defects. Uremic
subjects exhibit reduced glucose uptake in response to physiological
increments in plasma insulin concentration. The relative contributions
of insulin binding versus postbinding defects to this insulin resistance
are not known. Because insulin normally requires only a small portion
of its receptors to exert maximal biological effects on glucose uptake, it
should be possible to overcome the insulin resistance of uremia, if it is
due to a binding defect, by utilizing sufficiently high insulin levels to
draw on the large reserve of spare receptors. If postbinding defects are
present, however, then a decreased insulin response would be expected
at high insulin concentrations. To determine whether or not the insulin
resistance of uremia could be overcome by very high insulin levels, the
dose-response relationship between plasma insulin concentration and
insulin-mediated glucose uptake in seven chronically uremic and nine
control subjects was evaluated. Insulin was infused at rates of 20, 40,
200, and 400 mU/min'm2, and the plasma glucose concentration was
held constant at the basal level by a variable glucose infusion (euglyce-
mic insulin clamp technique). Under these steady state conditions of
euglycemia, the glucose infusion rate plus endogenous glucose produc-
tion (measured with 3H-3-glucose) provides a measure of the amount of
glucose taken up by the entire body. The steady state plasma insulin
concentrations during the four insulin infusion protocols in the uremic
subjects were consistently higher than in the controls. Despite the
higher insulin levels in the uremics, the total amount of glucose taken up
by the body was reduced by nearly 50% at each insulin plateau
compared to controls. These results indicate that the in vivo dose-
response curve relating plasma insulin concentration to glucose metab-
olism was shifted to the right in uremics and failed to normalize at high
insulin levels. Basal hepatic glucose production was similar in uremic
and control subjects. During the 20 and 40 mU/min'm2 insulin clamp
studies, suppression of hepatic glucose production in uremics (83 and
94%, respectively) was similar to controls (88 and 98%, respectively).
Specific '251-insulin binding to circulating monocytes was measured in
nine uremic and ten control subjects. No difference in insulin binding
between the uremics and controls was observed. In normals, insulin
binding correlated directly with glucose uptake and inversely with the
fasting plasma insulin concentration. In uremics, no correlation was
observed between insulin binding and glucose metabolism or between
insulin binding and fasting plasma insulin concentration, It is concluded
that in chronic renal failure insulin resistance is caused primarily by a
postbinding defect in insulin action.
La résistance a l'insuline dans l'urémie médiée par des anomalies
survenant aprés Ia liaison. Les urémiques ont une diminution de Ia
captation du glucose en réponse a des augmentations physiologiques de
Ia concentration plasmatique d'insuline. On ne connait pas le rOle relatif
des anomalies de Ia liaison de l'insuline et de celles survenant après Ia
liaison dans cette résistance a l'insuline. Puisque, normalement, I'insu-
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line n'a besoin que d'un petit nombre de récepteurs pour avoir ses effets
biologiques maximum sur Ia captation du glucose, il devrait étre
possible de dépasser cette résistance a I'insuline d l'urémie. si dIe était
due a un défaut de liaison, en utilisant des concentrations d'insuline
suffisamment élevées pour faire appel aux grandes quantités de récep-
teurs de reserve. Au contraire, si des anomalies après Ia liaison
existent, on pourrait s'attendre a one diminution de Ia réponse insuli-
nique pour de fortes concentrations d'insuline. Afin de determiner si Ia
résistance insulinique de l'urémie peut étre dépassee a de trés fortes
concentrations d'insuline, Ia relation effet-dose entre Ia concentration
plasmatique d'insuline et Ia captation du glucose dépendant de I'insu-
line chez sept urémiques chroniques et neuf sujets contrOles était
étudié. L'insuline était perfusée a des debits de 20, 40, 200 et 400 mU!
min'm2, et Ia glycemie était maintenue constante a sa valeur de base par
une perfusion de glucose a debit variable (technique du clamp insuli-
nique euglycemique). Dans ces conditions a I'équilibre euglycemique,
Ic debit de perfusion de glucose plus Ia production de glucose endogéne
(mesurée avec du 3H-3-glucose) fournit une mesure de Ia quantite de
glucose utilisée par l'organisme entier. Les concentrations plasma-
tiques d'insuline a l'état d'équilibre pendant les quatre protocoles de
perfusion insulinique chez les urémiques étaient significativement plus
hautes que Chez les contrôles. Malgré les plus fortes concentrations
d'insuline chez les urémiques, Ia quantité totale de glucose retenue par
l'organisme Ctait diminuCe d'environ 50% a chaque plateau insulinique,
par rapport aux contrôles. Ces résultats indiquent que Ia courbe dose-
réponse in vivo entre Ia concentration plasmatique d'insuline et Ic
métabolisme du glucose était décalée vers Ia droite chez les urémiques,
et ne s'est pas normalisée a de fortes concentrations d'insuline. La
production hepatique de base de glucose était identique chez les
urémiques et les contrôles. Au cours des etudes avec des debits
d'insuline de 20 et 40 mU/minm2, Ia suppression de Ia production
hépatique de glucose chez les urémiques était identique a celle des
contrôles. La liaison spécifique de 251 insuline a des monocytes
circulants a été mesurée chez neuf uremiques et dix contrOles. II na pas
été observe de difference entre Ia liaison de I'insuline chez les uré-
miques et chez les contrOles. Chez les normaux, Ia liaison insulinique
était directement corrélée avec l'entrée du glucose, et inversement
corrélée avec la concentration plasmatique d'insuline àjeOn. Chez les
urémiques, nous n'avons observe aucune correlation entre Ia liaison de
I'insuline et Ic métabolisme du glucose ni entre Ia liaison de l'insuline et
Ia concentration plasmatique d'insuline àjeOn. 11 est conclu qu'au cours
de l'insuffisance rénale chronique, Ia résistance a l'insuline est princi-
palement due a un défaut de l'action de I'insuline en aval de sa liaison.
Numerous studies performed over the past two decades have
established that insulin resistance is the major cause of the
glucose intolerance of uremia. The presence of elevated basal
concentrations of plasma immunoreactive insulin in uremic
subjects [1—5], the blunted response to insulin in forearm
perfusion studies [6], and the delayed and diminished hypogly-
cemic response after exogenous insulin [I, 5,7—12], and tolbuta-
mide [5, 7, 8, 11—13] provide evidence in support of this
concept.
Mechanisms of insulin resistance in uremia
More recent studies employing the euglycemic insulin clamp
technique have extended and clarified these observations [14].
It was observed that the endogenous insulin secretory response
to intravenous glucose was generally normal or increased,
whereas total body glucose uptake in response to both endoge-
nously secreted and intravenously infused insulin was uniform-
ly diminished in uremic subjects. This reduced insulin respon-
siveness was shown subsequently to reside primarily in periph-
eral tissues, most likely skeletal muscle [15].
Little information exists concerning the mechanism(s) of this
insulin resistance. Insulin, like other peptide hormones, is
thought to initiate its effects on target tissues by binding to
specific surface receptors [161. The resulting hormone-receptor
complex triggers a sequence of incompletely characterized
membrane and intracellular events which produce characteris-
tic biological responses. Thus, to evaluate the pathogenesis of
insulin resistance, it is necessary to evaluate both the insulin
binding as well as the postbinding steps.
Only a few studies of insulin binding in uremia have been
reported, and these are conflicting. Insulin binding to erythro-
cytes from chronically uremic, nondialyzed subjects was found
to be reduced [17]. After patients experienced hemodialysis
therapy for 1 year [18], erythrocyte binding was reported to be
increased above normal. In contrast, insulin binding to adipo-
cytes from uremic rats was not altered [19]. At present, it is not
possible to determine whether or not these differences are
accounted for by differences in the methods employed in each
study, by species variability, by the severity of uremia (and its
treatment), or by variation in insulin binding among different
tissues (that is, erythrocytes versus adipocytes).
Direct measurements of postbinding events in human muscle,
the tissue primarily responsible for glucose metabolism when
glucose and insulin are infused intravenously, are not possible
in vivo. However, inferences about their activity are possible
because of the distinctive relationship between insulin binding
and insulin action. Simultaneous measurements of insulin bind-
ing and insulin effects (for example, glucose transport) in
studies of muscle [201 and fat [21] in vitro have demonstrated
that insulin bioactivity increases rapidly with insulin concentra-
tion within the physiological range; however, bioactivity
reaches a plateau when only a small portion of the total number
of receptors is occupied, usually 5 to 20% [20, 21]. The
unoccupied, spare receptors appear to be identical to their
occupied counterparts, and the sequence in which receptors are
recruited is determined randomly [21]. Thus, at low hormone
concentrations, receptor occupancy is rate controlling for glu-
cose transport. However, at approximately 5 to 20% occupan-
cy, postbinding steps become saturated and thereby rate limit-
ing [22—24]. According to this scheme, in circumstances in
which alterations in insulin binding alone are responsible for
insulin resistance, the dose-response curve relating insulin
concentration to glucose uptake is shifted to the right; however,
the maximal hormone responsiveness is unaltered because the
high insulin concentrations will recruit sufficient spare recep-
tors to normalize the response. When postbinding abnormalities
are present, no amount of hormone is able to produce normal
maximal responsiveness. Although this is a simplification of a
very complex process, it does provide a framework which may
be helpful in distinguishing between binding versus postbinding
defects in insulin action.
To examine the contribution of altered insulin binding versus
postbinding defects in the insulin resistance of uremia, we
constructed in vivo dose-response curves relating total body
insulin-mediated glucose metabolism to the plasma insulin
concentration in seven chronically uremic subjects. In addition,
we correlated insulin-mediated glucose metabolism with mea-
sures of total, specific 1251-insulin binding to monocytes.
Methods
Subjects. Seven adult, ambulatory patients with advanced,
chronic renal failure served as the study population for the
euglycemic insulin clamp studies, All experiments were per-
formed in the Clinical Research Center of Yale-New Haven
Hospital. Diagnoses and relevant clinical and biochemical data
are presented in Table 1. All patients were within 20% of ideal
body weight (Metropolitan Life Insurance Tables, 1959). None
had a family history of diabetes mellitus, or clinical evidence of
diabetic retinopathy or neuropathy. All were edema free at the
time of study. Excluding one patient with chronic obstructive
lung disease, none had significant extrarenal disease. Blood
chemistries were normal or only slightly altered (Table I).
Except for sodium bicarbonate and aluminum hydroxide, no
patients were taking any medications for at least 3 days prior to
study. All subjects were free of gastrointestinal symptoms and
were consuming a weight maintaining diet containing at least
250 g of carbohydrate for 3 days prior to study. No subjects
were restricted in their protein intake.
Nine healthy volunteers of normal weight (four women and
five men) served as control subjects. Their ages ranged from 23
to 54 years (mean = 38 4 years). Their obesity index (ratio of
observed to ideal body weight) was 0.97 to 1.18 (mean = 1.05
0.03). The purpose and potential risks of the study were
explained to all subjects, and their written, voluntary consent
was obtained prior to their participation. The study protocol
was approved by the Human Investigations Committee of Yale
University School of Medicine. All tests were performed in the
postabsorptive state beginning at 8 A.M. following a 10-hr
overnight fast,
Euglycemic insulin clamp. A polyethylene catheter was in-
serted into an antecubital vein for infusion of insulin and
glucose. A second catheter was placed in a retrograde direction
in a wrist vein for blood sampling, and that hand was kept in a
heating box at 70° C to arterialize the venous blood [25].
Following collection of at least three baseline samples, a
primed-continuous infusion of crystalline porcine insulin (Eli
Lilly Co., Indianapolis, Indiana) was administered to raise
acutely and maintain the arterial plasma insulin concentration at
the desired level. The plasma glucose concentration was kept at
the basal level by determination of plasma glucose every 5 mm
and appropriate adjustment of the infusion rate of a 20% glucose
solution as previously described [26). Under these steady state
conditions of euglycemia, glucose input equals glucose utiliza-
tion. Glucose input is comprised of the exogenous infusion
required to maintain euglyceniia, and the endogenous glucose
production rate (see below); their sum thus serves as a measure
of the body's sensitivity to the infused insulin [26].
Each subject received a maximum of four insulin clamp
studies performed at approximately 1-week intervals to con-
struct a dose-response curve relating whole body sensitivity to
insulin to the plasma insulin concentration. The insulin infusion
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Table 1. Summary of clinical and laboratory data
Duration
Serum
Urea
Patient
no.
Age
year Sex
Ht
cm
Wt
kg
Obesity
index
of renal
failure° C.
Diagnosis year mi/mm
nitrogen Creatinine
----——
Phosphate HCO3 K
mEqlliter
Blood
pHmg/dl
1 50 M 177.8 79.5 1.17 Accelerated 2 9
nephrosclerosis
95 9.4 5.2 24 4.8 7.42
2 49 M 177.8 67.0 0.98 Chronic 5 24
glomerulonephritis
69 3.5 4.4 22 4.5 7.38
3 56 M 172.7 76.8 1.19 Chronic 9 15
glomerulonephritis
55 5.9 5.2 19 5.1 7.40
4 57 M 170.2 57.7 0.92 Chronic 10 18
glomerulonephritis
44 3.8 3.3 18 3.9 7.35
5 53 F 166.4 55.0 0.92 Membranous 12 11
glomerulopathy
106 4.6 5.7 25 3.9 7.43
6 42 M 180.2 84.2 1.20 Chronic 3 15
glomerulonephritis
96 6.5 5.0 19 4.7 7.35
7 19 M 177.8 63.2 0.93 Obstructive 10 7
nephropathy
92 15.9 6.5 20 4.2 7.33
Mean 46 174.7 69.1 1.04 7 14 80 7.1 5.0 21 4.4 7.38
SEM 5 1.9 4.3 0.05 2 2 9 1.7 0.4 1 0.2 0.01
a From the first known elevation in serum urea nitrogen and/or serum creatinine.
rate was varied over a 20-fold range (20, 40, 200, and 400 mU!
min•m2) to achieve increments in plasma insulin of approxi-
mately 50, 100, 500, and 1000 iU/m1. In the uremic group it was
feasible to perform 25 of the 28 desired studies; in the controls,
31 of 36. In each group, at least five subjects were studied at
each of the four insulin infusion rates.
Endogenous glucose production. The two lower dose clamp
studies were performed in conjunction with tritiated glucose to
measure the effect of hyperinsulinemia on hepatic glucose
production, as previously described [27]. For 120 mm in the
control group and 150 mm in the uremic group, each subject's
glucose pooi was labeled by a primed-continuous infusion of
3H-3-glucose (New England Nuclear, Boston, Massachusetts).
The labeled glucose was administered as a 25 Ci bolus fol-
lowed by a continuous infusion at the rate of 0.25 p.Ci/min.
Plasma samples for the determination of glucose specific activi-
ty were taken at —60 and —30 mm of this equilibration period,
and then every 5 mm until time 0 when the insulin infusion was
begun. A steady state of glucose specific activity was achieved
by this method in each study, and the specific activity plateau
was used to calculate glucose appearance in the basal state.
Because glucose production by nonhepatic tissues in the fasting
state is negligible, the rate of basal glucose appearance equals
hepatic glucose production. After this equilibration period, the
insulin clamp was begun and the tritiated glucose infusion
continued at the same rate. During the insulin clamp, plasma
samples for glucose specific activity were obtained at 15-mm
intervals for the first 90 mm, and then every 5 mm for the final
20 mm of the 2-hr study.
Insulin binding to monocytes. Nine subjects of normal weight
with chronic uremia (creatinine clearance = 15 1 ml/min)
gave blood samples for the determination of 1251-insulin binding
to monocytes. This group included three of the seven subjects
who participated in the dose-response study, three subjects
who received only 40 mU!minm2 insulin clamp, and three who
declined insulin clamp studies. Their ages ranged from 41 to 63
years (mean = 52 3 years). The obesity index was from 0.92
to 1.20 (mean = 1.09 0.04). Ten healthy volunteers of normal
weight served as controls, including six who also participated in
the dose-response study. Their ages ranged from 25 to 54 years
(mean = 42 3 years). Their obesity index was 0.88 to 1.18
(mean = 1.02 0.03).
Whole blood (100 ml) was drawn into heparinized syringes
(20 U/mI blood) from each subject following a 10-hr overnight
fast. The blood was diluted 1:1 with phosphate buffered saline,
pH 7.4, layered onto Ficoll-Hypaque, and centrifuged as de-
scribed by Boyum [28]. The mononuclear cell layer was re-
moved, washed once in chilled phosphate buffered saline, and
once in Hepes (N-2-hydroxyethylpiperazine-N'-2-ethanesul-
fonic acid) lymphocyte buffer (Hepes 100 m, sodium chloride
120 m, potassium chloride 5 m, EDTA 1 m, glucose 9 mM,
sodium acetate 15 m, magnesium sulfate 1.3 m, bovine
serum albumin 10 g/liter, pH 8.0). The final cell pellet was
diluted in Hepes buffer to a concentration of 35 to 45 x 106 cells!
ml. Viability was assessed by trypan blue exclusion, and was
always greater than 97%. For estimation of monocytes, 100 il
of the cell suspension, 10 of latex beads (10% solids, 0.8 p.m
diameter, Sigma, St. Louis, Missouri), and 0.5 ml of fetal calf
serum were incubated for 40 mm at 37° C in a shaking water
bath. Cells containing four or more beads were counted as
monocytes, and averaged 33 3% in the uremic group and 20
2% in the controls.
'251-insulin was prepared at a specific activity of 150 to 180
p.Ci/p.g by the chloramine-T method of Hunter and Greenwood
[29], as modified by Freychet et al [30]. Purified porcine insulin
for iodination was a gift of Lilly Research Laboratories, India-
napolis, Indiana, and sodium 1251 was purchased from ICN
(Irvine, California). '251-insulin (0.1 to 0.2 ng/ml) was incubated
with 0.4 ml of cell suspension with or without cold insulin in a
final incubation volume of 0.5 ml. The range of total insulin
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Table 2. Plasma insulin concentrations and glucose metabolism in the basal state and during euglycemic hyperinsulinemia (insulin clamp)°
Basal Insulin clamp
Fasting
plasma
insulin
Glucose
metabolismb
20 mlJ/minm2 40 mU/minm2 200 mU/min'm2 400 mU/minm2
—
SSPIC Md SSPI M SSPI M SSPI M
iUIml mg/mm kg p,U/ml mg/mmn'kg pU/mI mg/mm kg pU/mI mg/mm kg p.U/ml ,ng/minkg
Controls 14 1 2.2 0.1 69± 4 5.2 0.4 109 7 6.9 0.5 741 50 11.1 0.8 1880 182 11.5 0.6
Uremics 29 4e 2.1 0.1 84 12 2.7 0.2° 147 1Y 3.9 0.5° 1118 l27 6.5 0.7° 3181 367 7.0 0.6°
a All values are mean SEM.
Measured with 3H-3-glucose.
Steady state plasma insulin concentration during the 20- to 120-mm period.
"Mean rate of glucose uptake during the 20- to 120-mm period.
P < 0.01 compared to controls.
P < 0.05 compared to controls.
concentrations varied from 0.1 to 100,000 ng/ml. The incubation
was carried out in Hepes buffer for 180 mm at 22° C. After the
incubation, duplicate 0.2-mi aliquots of the cell suspension were
transferred to microfuge tubes containing 0.1 ml of chilled
Hepes buffer, and centrifuged at 10,000 RPM for 2 mm in a
Beckman Microfuge (Beckman Instruments, Inc., Fullerton,
California). The supernatant was removed by aspiration, and
the radioactivity in the cell pellet was counted in a gamma
counter. Nonspecific binding, as defined by the amount of 1251..
insulin bound to the cell pellet in the presence of l0 ng/ml
insulin, was 0.3 to 0.5% of total radioactivity for both normal
and uremic subjects. The nonspecific binding was subtracted
from total binding to give the specific binding, and this was
normalized to io monocytes/ml to facilitate comparisons.
Degradation of tracer by the incubation medium, as asessed by
1251 solubility in 10% trichioroacetic acid, was always less than
10% following the 3-hr incubation.
Analytical procedures. Plasma glucose was determined by
the glucose oxidase method (Glucostat, Beckman Instruments,
Inc., Fullerton, California). Methods for the determinations of
plasma immunoreactive insulin [31] and the specific activity of
plasma glucose [32] have been published previously. The inter-
and intra-assay variability for insulin determination was 10.2%
and 6.2%, respectively.
Calculations. For the euglycemic insulin clamp studies, the
glucose infusion rate was averaged over the final 20- to 1 20-mm
time period. The total amount of glucose metabolized by the
entire body (M) was calculated by adding the rate of endoge-
nous glucose production (see below) to the exogenous glucose
infusion rate required to maintain euglycemia. Steady state
plasma glucose and insulin levels were determined from the
mean values for the 20- to 120-mm time period.
Glucose turnover in the basal state was determined by
dividing the tritiated glucose infusion rate (cpm/min) by the
steady state glucose specific activity (cpm/mg) achieved during
the final 30 mm of the tracer equilibration period. After the
insulin infusion is begun, a nonsteady state condition for
glucose specific activity exists. The total rate of appearance of
glucose in the systemic circulation was then calculated from
Steele's equations in their derivative form [33], using a value of
0.65 for the pooi fraction [34]. The rate of endogenous (hepatic)
glucose production was estimated by subtracting the exogenous
infusion rate from the total appearance rate as calculated by the
isotopic tracer technique.
'251-insulin binding data were analyzed by three methods: (1)
competition curve, relating percent '251-insulin specifically
bound versus total (hot plus cold) insulin concentration; (2)
Scatchard plot, relating bound/free insulin versus bound insulin
[35]; and (3) average affinity profile method of De Meyts and
Roth, relating average insulin affinity (K1) for its receptor versus
fractional receptor occupancy [36].
All data are presented as mean SEM except where indicated
otherwise. All comparisons of mean values between groups
were calculated by unpaired t test analysis, and within groups
by paired t test analysis. Coefficients of correlation were
determined by standard procedures.
Results
Euglycemic insulin clamp. The basal glucose concentration
was similar in the uremic (94 4 mg/dl) and the control subjects
(92 2 mg/dl). In the 25 euglycemic insulin clamp studies
performed in uremic subjects, the plasma glucose was main-
tained at a steady state level of 94 2 mg/dl, with an average
coefficient of variation of 4.0 0.4%; in 31 studies performed in
the control group, the corresponding values were 91 1 mgldl
and 4.6 0.3%.
The basal plasma insulin concentration was higher in the
uremics than controls (29 4 U/ml versus 14 I U/ml, P <
0.01). The steady state insulin concentration from 20 to 120 mm
was also higher in the uremic group at each of the four insulin
infusion rates, although the difference was not significant in the
lowest dose study (Table 2). The stability of the plasma insulin
plateau is indicated by a coefficient of variation of 13.6 1.1%
in the uremic group, and 14.4 1.4% in the control group.
The total amount of glucose metabolized during each of the
four insulin clamp studies is shown in Table 2, The average rate
of glucose utilization was reduced by approximately 50% in all
four insulin infusion protocols. Figure 1 shows the dose-
response relationship between the plasma insulin concentration
and insulin-mediated glucose metabolism. The first point on
each curve represents the amount of fasting glucose metabolism
that is insulin-dependent. This has been approximated to repre-
sent 30% of basal hepatic glucose production [37]. The remain-
ing 70% of basal glucose metabolism, 1.49 0,04 mg/minkg in
the normals and 1.50 0.11 mg/minkg in the uremics, repre-
sents insulin-independent glucose metabolism and has been
subtracted from the total glucose metabolized during the eugly-
cemic insulin clamp studies. Because the 70% of the basal
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Fig. 1. Dose-response relationship between 1/se plasma insulin concen-
tration and insulin-mediated glucose metabolism in seven ure,nic
(I—--—I) and nine control (I—•) subjects. Insulin-dependent glu-
cose metabolism in the basal state (first point on each curve) was
assumed to be 30% of endogenous glucose production as determined
from 3H-3-glucose kinetics.
glucose metabolism which is insulin-independent is determined
only by glucose mass action, it would not be expected to change
under the euglycemic conditions employed in the present
studies. Although the 400 mU/minm2 insulin infusion rate
produced slightly higher mean rates of glucose metabolism in
each group in comparison to the 200 mU/minm2 insulin clamp
(Fig. 1), these differences were not statistically significant.
Thus, the responses in both groups appeared to achieve a
plateau with the 400 mU/minm2 insulin clamp studies. Com-
pared to normal, the dose-response curve for uremics had a
distinctly lower plateau (5.3 versus 9.3 mg/minkg, P < 0.001)
and was shifted to the right. Consequently, the plasma insulin
concentration required to achieve half-maximal stimulation of
glucose metabolism was significantly higher in the uremics (187
25 versus 96 11 U/m1, P < 0.01).
In Figure 2, the dose-response data of Table 2 are plotted as
insulin concentration versus percent of the maximal insulin
response (observed in the 400 mU/minm2 euglycemic insulin
clamp). Expressed in this way, the curve for uremics again
demonstrates a significant shift to the right.
Hepatic glucose production. In the basal state hepatic glu-
cose production in the uremics (2.14 0.10 mg/minkg) was
similar to that of controls (2.23 0.06 mglmin.kg). In the 20 and
40 mU/minm2 euglycemic insulin clamp studies, glucose pro-
duction by the liver suppressed by 83 and 94% in the uremics;
the degree of suppression was not different from the corre-
sponding control values, 88 and 98%. The time course of
suppression over the 2-hr study was similar in both groups.
Monocyte binding. The competition curves for total, specific
'251-insulin binding to monocytes is shown in Figure 3. Al-
though five of the nine observations in uremics were outside the
range of normals, the mean binding (5.9 0.6%) was similar to
the control value (6.2 0.2%). The half-maximal binding
occurred at identical insulin concentrations in the two groups
(2.4 ng/ml). Scatchard analysis of the binding data revealed very
similar curves with identical x-axis extrapolations (1.3 ng/ml).
The total number of insulin receptors per cell was similar in
uremic (11,000 2000) and control groups (15,000 2000).
Average affinity profiles were also similar, with average affinity
of the unoccupied receptor in the uremic group (3.2/10 nM)
slightly but not significantly less than that of the control group
(3.6/10 flM).
In normal subjects, total '25I-insulin specifically bound to
monocytes correlated directly (r = 0.67, P < 0.05) with the total
glucose metabolism observed in the 40 mU/minm2 insulin
clamp (Fig. 4). In contrast, there was no apparent relationship
between these variables in uremic subjects. There was a
significant inverse correlation between the fasting plasma insu-
lin concentration and '251-insulin binding to monocytes in
normal (r = 0.76, P < 0.05) but not in uremic subjects (Fig. 5).
Discussion
Under the conditions of euglycemic hyperinsulinemia em-
ployed in the present studies, the splanchnic bed of both normal
and uremic subjects is known to utilize similar, small amounts
of glucose [15, 38]. Also, suppression of hepatic glucose pro-
duction is similar. Thus, by exclusion, the blunted response to
exogenous insulin observed in our uremic patients (Fig. 1) must
result from peripheral, that is, extra-splanchnic, resistance to
the action of insulin. Moreover, because fat accounts for only a
small percentage of insulin-mediated glucose uptake [391, the
defect most likely resides predominantly in skeletal muscle.
This conclusion is consistent with the original observation of
Westervelt that stimulation of glucose uptake by insulin is
attenuated in forearm perfusion studies of uremic patients [61.
Similar findings were subsequently reported with the hindlimb
perfusion technique in uremic rats [401, and with leg catheter-
ization in uremic patients [15]. It should be pointed out,
however, that fat (as well as other tissues) could be severely
resistant to the action of insulin but this would have little impact
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Fig. 2. Dose-response relationship between the plasma insulin concen-
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on glucose metabolism as measured with the euglycemic insulin
clamp technique. In fact, recent studies in uremic rats have
demonstrated specific defects in adipocyte glucose metabolism
[19].
The cellular mechanism underlying this impairment in insulin
action remains to be elucidated. The relationship between the
plasma insulin concentration and glucose metabolism is com-
plex. The determinants of this relationship include insulin
binding, which in turn is conditioned by insulin receptor num-
ber and affinity; by postbinding activities of the receptor, such
as aggregation, internalization, and degradation [411; by the
number and activity of glucose transport systems [42]; and by
intracellular pathways for glucose disposal [43]. Furthermore,
the insulin response in vivo represents the simultaneous activi-
ties of multiple insulin responsive tissues, which may be
differentially affected by the hormone. Despite these complex-
ities, it is possible to examine the mechanism(s) of insulin
resistance in vivo because of the characteristic relationship
between insulin binding and insulin action.
Stephenson proposed many years ago that the biological
effects of hormonal stimulation might occur when less than the
total number of cell surface receptors were bound by the
hormone [24]. Subsequently, animal studies from many labora-
tories have confirmed this hypothesis. Both adipocytes [21, 44]
and isolated soleus muscle [20, 45] achieve maximal glucose
uptake when only a small fraction (5 to 20%) of sui-face insulin
receptors are bound. Reduction in the number of receptors by
trypsin exposure [211, spontaneous obesity [44], or experimen-
tal obesity [45] does not impair the maximal insulin response
unless the number of receptors is decreased by more than 80 to
95% [21]. Similar observations have been made in human
subjects. Kolterman et al have estimated that maximal rates of
glucose disposal in normal subjects (measured by the euglyce-
mic insulin clamp) are achieved when at most 40% of insulin
receptors on adipocytes are occupied [46]. Thus, it would
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Fig. 4. Relationship between 251-insulin specifically bound to mono-
cytes and glucose metabolism (40 mUI,ninm2 insulin clamp) in control
(left panel) and uremic (right panel) subjects who participated in the
dose-response study (U), or who received only the 40 mU/minm2
insulin clamp (•).
appear to be a general phenomenon that the majority of insulin
receptors are unoccupied at hormone concentrations capable of
eliciting a maximal functional response. Even though all of the
receptors are presumably capable of normal function [47], at
low fractional occupancy some postbinding activity becomes
rate limiting for hormone action. Observations of this sort have
led to the proposal that mechanisms for insulin resistance could
be inferred from the shape and position of the dose-response
curve for insulin action [48, 49]. An isolated defect in insulin
binding would be expected to result in a rightward shift in the
dose-response curve, with a normal response occurring at
higher insulin concentrations, provided that the minimal num-
ber of receptors normally required for a maximal response
still remains. In contrast, a postbinding defect would produce
a decreased response to maximally effective insulin
concentrations.
The data presented in this report demonstrate both a right-
ward shift as well as decreased maximal responsiveness in the
dose-response curve relating plasma insulin concentration to
glucose metabolism in uremic subjects. Because insulin binding
was normal, these results are most compatible with an isolated
postbinding defect in insulin-mediated glucose metabolism. It is
important, however, to ketp in mind the assumptions behind
this conclusion. During the insulin clamp study, the major site
of glucose uptake is muscle. It must be assumed, therefore, that
spare receptors exist in human muscle as they do in rodent
muscle [20] and human adipocytes [46]. It also must be assumed
that a postbinding defect cannot be overcome at high insulin
concentrations. Although this appears to be the case in rodent
obesity for both adipocytes [44] and skeletal muscle [20, 45], it
has not been established for either tissue in man.
It is also of interest to examine the data relating the plasma
insulin concentration and insulin-mediated glucose metabolism
in terms of the percent of maximal response. Kolterman et al
have suggested that if the biological response data are normal-
ized to the percent of maximum, postbinding contributions to
altered glucose utilization may be eliminated [46]. Consequent-
ly, this mode of data expression should reveal directly any
contribution of impaired insulin binding to the insulin resist-
ance. For a simple system involving a single tissue with a single
rate limiting intracellular step, if one plots the dose-response
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data in this way (percent of maximal response) an isolated
postbinding defect would be manifested by a normal curve.
However, in man in vivo where multiple tissues and processes
(that is, muscle, adipose, hepatic, extrahepatic splanchnic
glucose uptake, and suppression of hepatic glucose production)
contribute to the overall rate of glucose utilization and where
multiple intracellular steps may be rate limiting, the ascending
or steep portion of the insulin dose-response curve may be
difficult to interpret and a rightward shift may or may not be
present. Figure 2 depicts a plot of the insulin concentration
versus the percent of maximum response for our uremic sub-
jects; a significant shift to the right for the uremics was
observed. Because insulin binding was normal, these results
suggest that postbinding defects in insulin action in man may
also be accompanied by a rightward shift in the percent
maximum dose-response curve, so that caution must be used in
interpreting this complex relationship.
Of the six subjects who received both an insulin binding study
and a 40 mU/minm2 insulin clamp study, all demonstrated
significant reductions in insulin-mediated glucose metabolism,
while only one had decreased insulin binding. It should be
noted, however, that the insulin binding studies were carried
out on circulating monocytes. It is known that this cell type
does not demonstrate the full range of biologic responses to
insulin. Furthermore, the incubation conditions (pH, tempera-
ture and buffer), designed to optimize binding and minimize
degradation of the tracer, are unphysiologic. Accordingly,
whether or not monocyte binding accurately reflects binding in
conventional insulin target tissues in vivo can be argued.
Nevertheless, considerable evidence suggests that they are well
correlated. For example, Gavin et al have shown that the
insulin binding properties of the human monocyte are very
similar to those of liver and fat [50]. SoIl et al demonstrated that
insulin binding to thymic lymphocytes from obese mice paral-
lels insulin binding alterations in hepatocytes and adipocytes
[51]. More recently Olefsky reported similar insulin binding
changes in monocytes and adipocytes from obese patients [521.
In the present investigation, however, insulin-mediated glucose
metabolism is determined primarily by the hormone's effects on
two tissues, liver and skeletal muscle. To our knowledge, no
one has reported data on insulin binding to human muscle or
liver and correlated this with insulin binding to monocytes.
Until such data are available, the present insulin binding studies
should be interpreted cautiously.
With the above reservations in mind, it is interesting to
examine the correlation between insulin binding and insulin
action observed in these studies. During the 40 mU/minm2
insulin clamp study, insulin-mediated glucose metabolism in the
control group correlated directly with monocyte binding at
tracer insulin concentration (Fig. 4). In contrast, there was no
correlation between these measurements in the uremic group. A
—i similar dissociation between insulin binding and insulin action
70 has been demonstrated previously in such diverse circum-
stances as high carbohydrate feeding [53], starvation [54], and
noninsulin-dependent diabetes mellitus [55]. Chronic renal fail-
ure appears to be another condition in which the normal
relationship between insulin binding and responsiveness can be
disrupted.
Many previous studies have demonstrated a negative correla-
tion between the fasting plasma insulin concentration and
insulin binding to its receptor, fostering the current view that
the basal insulin level is the major factor responsible for
regulating its receptor concentration [41]. In agreement with
this hypothesis, an inverse relationship (r =
—0.76, P < 0.05)
between insulin binding to monocytes and the fasting plasma
insulin concentration was observed in our control subjects (Fig.
5). In contrast, no correlation between these variables was
observed in the uremic group. Despite fasting insulin levels that
were twice those in the controls (29 versus 14 iiUlml), mean
insulin binding was not diminished in the uremics. Even in the
two subjects with the highest fasting insulin levels (52 and 30
U/ml), no decrease in monocyte binding was observed (5.1
and 6.2%, respectively). Our results seem to indicate that in
many uremic individuals, factors in addition to insulin play a
role in regulating receptor activity. In this regard, a recent
report by Caro and Amatruda indicates that the ability of insulin
to regulate receptor activity is mediated by postreceptor events
[56]. These authors suggested that the presence of normal
insulin binding in some insulin resistance states may result from
resistance to this regulatory effect of insulin on its own receptor
concentration. Alternatively, normal binding in insulin-resistant
states may represent a compensatory process by as yet unde-
fined mechanisms.
In previous studies of uremic subjects which employed
tritiated glucose in conjunction with the hepatic venous cathe-
terization technique, we have shown that elevation of the
plasma insulin concentration by approximately 100 pU/ml
inhibited hepatic glucose production normally [15]. The present
results extend these earlier observations by examining suppres-
sion of hepatic glucose at a lower plasma insulin concentration
(55 U/ml). In these lower dose insulin clamp studies, a similar
inhibition of hepatic glucose production was observed in uremic
and control subjects (83 and 88%, respectively). These results
indicate that within the physiological range of insulin concentra-
tions the liver of uremic man retains normal sensitivity to
insulin, at least with respect to suppression of glucose
production.
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